Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockou...
Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Sodium glucose co-transporter2 inhibitors reduce the incidence of cardiovascular events in patients with type 2 diabetes mellitus based on the results of recent cardiovascular outcome studies. Herein, we investigated the effects of long-term treatment with canagliflozin on biochemical and immunohistochemical markers related to atherosclerosis and a...
Alternative Titles
Full title
Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_29be01d1c57c4de18eac7a2c4b1661db
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_29be01d1c57c4de18eac7a2c4b1661db
Other Identifiers
ISSN
1475-2840
E-ISSN
1475-2840
DOI
10.1186/s12933-018-0749-1
